Biomedical research aiming to improve genetic disorders
The goal of the NIH Common Fund Somatic Cell Genome Editing (SCGE) Program is to improve and accelerate translation of genome editing technology into disease treatments. SCGE Phase 1 focused on new genome editors, delivery technologies, in vivo cell tracking, new animal models and human biological systems, and dissemination through the Toolkit. SCGE Phase 2 focuses on translation of in vivo genome editing therapies into the clinic.
The exhibit will provide access to NIH Program representatives, live SCGE Toolkit demos, and materials about Phase I and 2 of the program.